Dozens of medical marijuana dispensaries are sprinkled in cities across the state, and Detroit has 61 pot shops open for business. But come this time next year, the landscape for weed around the state could be completely different.
That’s when the state will begin officially handing out licenses to growers, testing facilities, transporters and dispensaries.
The state Department of Licensing and Regulatory Affairs (LARA) is beginning to gear up for the task of regulating a new, and potentially very lucrative, business in the state. The medical marijuana business is projected to generate revenues of more than $700 million, and if a ballot proposal goes to voters in 2018 and the market is opened for recreational use, too, those revenues will easily surpass $1 billion.
“Most states have had two years to get this going,” said Shelly Edgerton, director of LARA. “For us, this is a huge endeavor.”
Andrew Brisbo, who has served as LARA’s licensing division director, has been named as the director of the newly created Bureau of Medical Marijuana Regulation. He will be in charge of the department that could grow to nearly 100 employees who investigate all license applicants and ultimately regulate the medical marijuana business and administer the system that tracks medical marijuana from seed to sale. [Read more at Detroit Free Press]
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Notify me of follow-up comments by email.
Notify me of new posts by email.
POSaBIT, the cannabis point-of-sale (POS) and payments software company, this morning announced its planned acquisition of MJ Platform (MJ Freeway), Leaf Data Systems, and Ample Organics from embattled software company…
New York marijuana regulators on Wednesday approved dozens of conditional adult-use dispensary licenses in a session during which members also discussed adopting bylaws for how the board runs meetings and makes decisions.…
By Griffin Thorne, Attorney at Harris Bricken Since the passage of the 2018 Farm Bill, the hemp CBD industry has been eagerly awaiting FDA CBD regulations. In that time, FDA…
The US Food and Drug Administration has finalized a 2020 draft guidance outlining how sponsors and investigators can conduct clinical trials for certain drugs containing cannabis or cannabis-derived compounds without…